CCR2 and central nervous system cancer: Additionally, monotherapy with CCX872, a CCR2 antagonist, improved median survival in an orthotopic model induced by KR158 glioma cells; these antitumor effects were further enhanced by the combination of CCX872 with anti-PD-1 [113].